407 related articles for article (PubMed ID: 16728570)
1. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
[TBL] [Abstract][Full Text] [Related]
5. 3T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-gamma-dependent and mediated by the caspase-3-dependent apoptotic pathway.
Xiao Y; Yuan T; Yao W; Liao K
FEBS J; 2010 Feb; 277(3):687-96. PubMed ID: 20050918
[TBL] [Abstract][Full Text] [Related]
6. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
8. Development of small-molecule cyclin D1-ablative agents.
Huang JW; Shiau CW; Yang J; Wang DS; Chiu HC; Chen CY; Chen CS
J Med Chem; 2006 Jul; 49(15):4684-9. PubMed ID: 16854074
[TBL] [Abstract][Full Text] [Related]
9. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
Huang JW; Shiau CW; Yang YT; Kulp SK; Chen KF; Brueggemeier RW; Shapiro CL; Chen CS
Mol Pharmacol; 2005 Apr; 67(4):1342-8. PubMed ID: 15653552
[TBL] [Abstract][Full Text] [Related]
11. PPARgamma-independent antitumor effects of thiazolidinediones.
Wei S; Yang J; Lee SL; Kulp SK; Chen CS
Cancer Lett; 2009 Apr; 276(2):119-24. PubMed ID: 18790559
[TBL] [Abstract][Full Text] [Related]
12. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells.
Cheng Y; Ping J; Xu LM
Chin Med J (Engl); 2007 May; 120(9):794-801. PubMed ID: 17531121
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro.
Liu JJ; Liu PQ; Lin DJ; Xiao RZ; Huang M; Li XD; He Y; Huang RW
Ann Hematol; 2007 Mar; 86(3):173-83. PubMed ID: 17089125
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.
Fu L; Xiong X; Wang L; Gao X; Ye Y; Jia J; Hu H; Li L; Shen J; Mei C
Chemotherapy; 2009; 55(6):468-76. PubMed ID: 19996593
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells.
Lovekamp-Swan T; Chaffin CL
Mol Cell Endocrinol; 2005 Apr; 233(1-2):15-24. PubMed ID: 15767042
[TBL] [Abstract][Full Text] [Related]
19. Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.
Coyle AT; Kinsella BT
Biochem Pharmacol; 2006 Apr; 71(9):1308-23. PubMed ID: 16499875
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.
Yang CC; Ku CY; Wei S; Shiau CW; Chen CS; Pinzone JJ; Ringel MD; Chen CS
Mol Pharmacol; 2006 May; 69(5):1564-70. PubMed ID: 16452400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
